

# Heidi Schilter

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8956832/heidi-schilter-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

9

papers

196

citations

7

h-index

9

g-index

9

ext. papers

269

ext. citations

6.2

avg, IF

2.63

L-index

#	Paper	IF	Citations
9	An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies. <i>Clinical and Translational Medicine</i> , <b>2021</b> , 11, e572	5.7	3
8	Therapeutic targets in lung tissue remodelling and fibrosis. <i>Pharmacology &amp; Therapeutics</i> , <b>2021</b> , 225, 107839	13.9	25
7	Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy. <i>PLoS ONE</i> , <b>2020</b> , 15, e0234617	3.7	3
6	Identification and Optimization of Mechanism-Based Fluoroallylamine Inhibitors of Lysyl Oxidase-like 2/3. <i>Journal of Medicinal Chemistry</i> , <b>2019</b> , 62, 9874-9889	8.3	19
5	The lysyl oxidase like 2/3 enzymatic inhibitor, PXS-5153A, reduces crosslinks and ameliorates fibrosis. <i>Journal of Cellular and Molecular Medicine</i> , <b>2019</b> , 23, 1759-1770	5.6	49
4	The mannose-6-phosphate analogue, PXS64, inhibits fibrosis via TGF- $\beta$ pathway in human lung fibroblasts. <i>Immunology Letters</i> , <b>2015</b> , 165, 90-101	4.1	9
3	Effects of an anti-inflammatory VAP-1/SSAO inhibitor, PXS-4728A, on pulmonary neutrophil migration. <i>Respiratory Research</i> , <b>2015</b> , 16, 42	7.3	36
2	Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model. <i>American Journal of Physiology - Renal Physiology</i> , <b>2014</b> , 307, F908-16	4.3	15
1	PXS-4681A, a potent and selective mechanism-based inhibitor of SSAO/VAP-1 with anti-inflammatory effects in vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2013</b> , 347, 365-74	4.7	37